Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 28, 2026
DataAggregated Company Financials
Companies551
  • 7D-3.1%
  • 3M-1.3%
  • 1Y31.1%
  • YTD3.1%

Over the last 7 days, the Biotech industry has dropped 3.1%, driven by a pullback from AbbVie of 3.1%. Meanwhile, Inhibrx Biosciences actually outperformed within the industry, gaining 60% in the last week. Over the past 12 months, the industry was up 31%. Looking forward, earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 28 Apr 2026US$1.3tUS$166.0b-US$11,971,624,927.8917.3x-107.7x7.8x
Thu, 26 Mar 2026US$1.2tUS$166.1b-US$14,897,815,988.9015.7x-83.1x7.4x
Sat, 21 Feb 2026US$1.3tUS$168.0b-US$13,498,381,572.3922.1x-99.6x8x
Mon, 19 Jan 2026US$1.2tUS$163.5b-US$15,150,311,707.6019.7x-80.8x7.5x
Wed, 17 Dec 2025US$1.2tUS$163.7b-US$15,629,818,633.6018.6x-78.1x7.5x
Fri, 14 Nov 2025US$1.2tUS$163.8b-US$16,256,883,029.7417.8x-73.3x7.3x
Sun, 12 Oct 2025US$1.1tUS$163.4b-US$18,215,104,196.5216.6x-62.2x6.9x
Tue, 09 Sep 2025US$1.1tUS$163.6b-US$18,335,721,970.2215.3x-59.5x6.7x
Thu, 07 Aug 2025US$1.0tUS$161.7b-US$14,985,569,307.7316.9x-67.1x6.2x
Sat, 05 Jul 2025US$960.2bUS$155.8b-US$23,415,675,000.5617.3x-41x6.2x
Mon, 02 Jun 2025US$908.2bUS$155.9b-US$23,672,769,787.0415.6x-38.4x5.8x
Wed, 30 Apr 2025US$795.9bUS$119.3b-US$30,922,989,483.0020.4x-25.7x6.7x
Fri, 28 Mar 2025US$816.7bUS$118.6b-US$37,006,972,359.4322.1x-22.1x6.9x
Sun, 23 Feb 2025US$863.3bUS$117.3b-US$37,606,528,073.3717x-23x7.4x
Tue, 21 Jan 2025US$947.4bUS$149.4b-US$26,290,369,541.3617.3x-36x6.3x
Thu, 19 Dec 2024US$1.0tUS$149.9b-US$26,462,738,539.2415.4x-37.8x6.7x
Sat, 16 Nov 2024US$1.0tUS$150.0b-US$26,800,374,726.0816x-38.7x6.9x
Mon, 14 Oct 2024US$902.0bUS$113.1b-US$36,040,263,614.5420.6x-25x8x
Wed, 11 Sep 2024US$894.1bUS$113.1b-US$35,660,564,622.3222.3x-25.1x7.9x
Fri, 09 Aug 2024US$1.2tUS$166.7b-US$32,150,549,450.8023.9x-36.2x7x
Sun, 07 Jul 2024US$1.1tUS$164.5b-US$28,073,537,735.6427.9x-40.3x6.9x
Tue, 04 Jun 2024US$1.1tUS$164.6b-US$26,680,256,870.3727.7x-42.1x6.8x
Thu, 02 May 2024US$1.1tUS$165.0b-US$26,426,226,136.7823.2x-41x6.6x
Sat, 30 Mar 2024US$1.2tUS$164.4b-US$23,362,713,195.1520.8x-50.5x7.2x
Mon, 26 Feb 2024US$1.2tUS$166.6b-US$21,694,939,476.2110.8x-54.3x7.1x
Wed, 24 Jan 2024US$1.4tUS$204.7b-US$22,529,001,992.0018.1x-63.5x7x
Fri, 22 Dec 2023US$1.3tUS$204.8b-US$22,148,191,573.0019x-60x6.5x
Sun, 19 Nov 2023US$1.2tUS$204.7b-US$22,079,556,420.0018.1x-54.7x5.9x
Tue, 17 Oct 2023US$1.3tUS$207.4b-US$13,067,799,538.0017.3x-97.1x6.1x
Thu, 14 Sep 2023US$1.3tUS$207.5b-US$12,611,945,630.0017.6x-101.4x6.2x
Sat, 12 Aug 2023US$1.3tUS$207.7b-US$12,540,100,481.0017.1x-102.7x6.2x
Mon, 10 Jul 2023US$1.1tUS$186.3b-US$16,022,507,026.0012.9x-69.1x5.9x
Wed, 07 Jun 2023US$1.1tUS$185.9b-US$16,017,335,337.0011.6x-71.1x6.1x
Fri, 05 May 2023US$1.2tUS$193.7b-US$11,169,713,239.0014.5x-103.6x6x
Price to Earnings Ratio

-103.6x


Total Market Cap: US$1.2tTotal Earnings: -US$11,169,713,239.00Total Revenue: US$193.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -57.7x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 7.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 5.0% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.72%
Healthcare-2.64%
Biotech-3.11%
Biotech-3.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
INBX Inhibrx BiosciencesUS$131.4559.6%
+US$716.7m		964.4%PS1477x
ARWR Arrowhead PharmaceuticalsUS$73.606.3%
+US$609.1m		444.4%PE51x
ANAB AnaptysBioUS$66.5930.7%
+US$449.6m		212.2%PS8.2x
CPRX Catalyst PharmaceuticalsUS$29.2712.3%
+US$390.8m		23.9%PE16.7x
ORKA Oruka TherapeuticsUS$76.3910.9%
+US$377.5m		643.1%PB8.2x

Latest News

CPRX
US$29.27
Catalyst Pharmaceuticals
7D
12.3%
1Y
23.9%
ORKA
US$76.39
Oruka Therapeutics
7D
10.9%
1Y
643.1%
CELC
US$125.68
Celcuity
7D
4.7%
1Y
1,033.3%
RCUS
US$24.95
Arcus Biosciences
7D
9.7%
1Y
202.4%

Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now

Apr 27
MRNA
US$48.70
Moderna
7D
-10.2%
1Y
75.1%

MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside

Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.
AMGN
US$340.18
Amgen
7D
-1.4%
1Y
17.9%
ARWR
US$73.60
Arrowhead Pharmaceuticals
7D
6.3%
1Y
444.4%
ANAB
US$66.59
AnaptysBio
7D
30.7%
1Y
212.2%
INBX
US$131.45
Inhibrx Biosciences
7D
59.6%
1Y
964.4%
RVMD
US$131.67
Revolution Medicines
7D
-10.0%
1Y
217.5%

Progress Against Pancreatic Cancer - Part 1

Apr 23
ABBV
US$197.38
AbbVie
7D
-3.1%
1Y
2.6%

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.
GILD
US$127.75
Gilead Sciences
7D
-4.2%
1Y
22.6%
VRTX
US$426.01
Vertex Pharmaceuticals
7D
-3.0%
1Y
-14.2%

Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings

Apr 22
EXEL
US$44.65
Exelixis
7D
2.4%
1Y
16.2%
ONC
US$298.90
BeOne Medicines
7D
-6.0%
1Y
19.8%
SMMT
US$22.12
Summit Therapeutics
7D
-11.9%
1Y
-8.3%